Articles related to SKIN CANCER

Curettage and cryosurgery is a safe and effective treatment method for basal cell carcinoma. The method is well tolerated by patients and has a low recurrence rate.

Discover how to navigate the evolving therapeutic landscape for advanced melanoma, with a focus on the latest immunotherapies, mitigation of treatment-associated adverse events, and patient-centric strategies to enhance shared decision-making and quality of life.

Explore the intricacies of squamous-cell carcinoma of the skin treatment, from the role of adjuvant therapy to the importance of close clinical surveillance, particularly in immunosuppressed patients.

The Hall-of-Fame quarterback recently alerted worried viewers about the diagnosis of the rare disease after he felt some pain in his neck. Ultimately, the diagnosis changed his outlook on life. “We’re going to go to Europe, going to go to Paris, going to go to wherever we want to go. I’m going to get all this in because I feel like I don’t want to put this off anymore … I may have 25, 30 years left, but I’m going to act like I got one.” Terry Bradshaw

Neoadjuvant cemiplimab was administered to a total of 79 individuals. Upon independent review, a pathological complete response (51 percent; 95% confidence interval [CI], 39 to 62) was noted in 40 patients, and a pathological substantial response (13 percent; 95% CI, 6 to 22) was noted in 10 patients. These outcomes matched the abnormal reactions identified during the investigator’s examination. Fifty-four (54) patients (68%; 95% CI, 57 to 78) had an objective response on imaging, and 69 individuals (87%) experienced adverse events of any grade that happened throughout the course of the study, regardless of whether they were linked to the study treatment. Fourteen (14) participants (18%) experienced adverse events of grade 3 or higher during the research period.

Cancer Therapy Advisor provides a variety of resources, including regimens used to supplement the most recent treatment strategies. Examine all regimens here.